Friday, August 23 2019
  1. Biological Evaluation of the Antiproliferative and Anti-migratory Activity of a Series of 3-(6-Phenylimidazo[2,1-b][1,3,4]thiadiazol-2-yl)-1H-indole Derivatives Against Pancreatic Cancer Cells. Li Petri G, Cascioferro S, El Hassouni B, Carbone D, Parrino B, Cirrincione G, Peters GJ, Diana P, Giovannetti E. Anticancer Res. 2019 Jul;39(7):3615-3620.
  2. Uridine Cytidine Kinase 2 as a Potential Biomarker for Treatment with RX-3117 in Pancreatic Cancer. El Hassouni B, Infante J, Mantini G, Ricci C, Funel N, Giovannetti E, Peters GJ.. Anticancer Res. 2019 Jul;39(7):3609-3614
  3. A Brief Guide to Performing Pharmacological Studies In Vitro: Reflections from the EORTC-PAMM Course "Preclinical and Early-phase Clinical Pharmacology. Capula M, Corno C, El Hassouni B, Li Petri G, Aranđelović S; EORTC PAMM Group. Anticancer Res. 2019 Jul;39(7):3413-3418.
  4. To Combine or Not Combine: Drug Interactions and Tools for Their Analysis. Reflections from the EORTC-PAMM Course on Preclinical and Early-phase. Clinical Pharmacology El Hassouni B, Mantini G, Li Petri G, Capula M, Boyd L, Weinstein HNW, Vallés-Marti A, Kouwenhoven MCM, Giovannetti E, Westerman BA, Peters GJ; EORTC PAMM Group. Anticancer Res. 2019 Jul;39(7):3303-3309.
  5. Laser Capture Microdissection and RNA-Seq Analysis: High Sensitivity Approaches to Explain Histopathological Heterogeneity in Human Glioblastoma FFPE Archived Tissues. Civita P, Franceschi S, Aretini P, Ortenzi V, Menicagli M, Lessi F, Pasqualetti F, Naccarato AG, Mazzanti CM.. Front Oncol. 2019 Jun  7;9:482.
  6. Rescuing cones and daylight vision in retinitis pigmentosa mice. Guadagni V, Biagioni M, Novelli E, Aretini P, Mazzanti CM, Strettoi E. FASEB J. 2019 Jun 14:fj201900414R.
  7. Molecular profiling of microinvasive breast cancer microenvironment progression. Lessi F, Scatena C, Aretini P, Menicagli M, Franceschi S, Naccarato AG, Mazzanti CM. J Transl Med. 2019 Jun 3;17(1):187.
  8. Pharmacogenetics of treatments for pancreatic cancer. El Hassouni B, Li Petri G, Liu DSK, Cascioferro S, Parrino B, Hassan W, Diana P, Ali A, Frampton AE, Giovannetti E.  Expert Opin Drug Metab Toxicol. 2019 Jun;15(6):437-447.
  9. Decrease in phospho-PRAS40 plays a role in the synergy between erlotinib and crizotinib in an EGFR and cMET wild-type squamous non-small cell lung cancer cell line. Van Der Steen N, Leonetti A, Keller K, Dekker H, Funel N, Lardon F, Ruijtenbeek R, Tiseo M, Rolfo C, Pauwels P, Peters GJ, Giovannetti E. Biochem Pharmacol. 2019 Aug;166:128-138.
  10. Role of c-MET Inhibitors in Overcoming Drug Resistance in Spheroid Models of Primary Human Pancreatic Cancer and Stellate Cells. Firuzi O, Che PP, El Hassouni B, Buijs M, Coppola S, Löhr M, Funel N, Heuchel R, Carnevale I, Schmidt T, Mantini G, Avan A, Saso L, Peters GJ, Giovannetti E. Cancers (Basel). 2019 May 8;11(5). pii: E638.
  11. Nanocarriers for Protein Delivery to the Cytosol: Assessing the Endosomal Escape of Poly(Lactide-co-Glycolide)-Poly(Ethylene Imine) Nanoparticles. Galliani M, Tremolanti C, Signore G. Nanomaterials (Basel). 2019 Apr 23;9(4). pii: E652.
  12. MICAL2 is expressed in cancer associated neo-angiogenic capillary endothelia and it is required for endothelial cell viability, motility and VEGF response. Barravecchia I, Mariotti S, Pucci A, Scebba F, De Cesari C, Bicciato S, Tagliafico E, Tenedini E, Vindigni C, Cecchini M, Berti G, Vitiello M, Poliseno L, Mazzanti CM, Angeloni D. Biochim Biophys Acta Mol Basis Dis. 2019 Apr 18. pii: S0925-4439(19)30119-X.
  13. Monoallelic expression in melanoma. Silcock L, Almabrazi H, Mokrab Y, Jithesh P, Al-Hashmi M, James N, Mathew R, Mattei V, Bedognetti D, Lessi F, Temanni R, Seliger B, Al-Ali R, Marincola FM, Wang E, Tomei S. J Transl Med. 2019 Apr 5;17(1):112.
  14. Overexpression of the cohesin-core subunit SMC1A contributes to colorectal cancer development. Sarogni P, Palumbo O, Servadio A, Astigiano S, D'Alessio B, Gatti V, Cukrov D, Baldari S, Pallotta MM, Aretini P, Dell'Orletta F, Soddu S, Carella M, Toietta G, Barbieri O, Fontanini G, Musio A. J Exp Clin Cancer Res. 2019 Mar 1;38(1):108.
  15. 2,6-Disubstituted imidazo[2,1-b][1,3,4]thiadiazole derivatives as potent staphylococcal biofilm inhibitors. Cascioferro S, Parrino B, Petri GL, Cusimano MG, Schillaci D, Di Sarno V, Musella S, Giovannetti E, Cirrincione G, Diana P. Eur J Med Chem. 2019 Apr 1;167:200-210.
  16. Molecular characterization of low grade and high grade bladder cancer. Apollo A, Ortenzi V, Scatena C, Zavaglia K, Aretini P, Lessi F, Franceschi S, Tomei S, Sepich CA, Viacava P, Mazzanti CM, Naccarato AG.. PLoS One. 2019 Jan 16;14(1):e0210635.
  17. Integrative Clustering in Mass Spectrometry Imaging for Enhanced Patient Stratification. Balluff B, Buck A, Martin-Lorenzo M, Dewez F, Langer R, McDonnell LA, Walch A, Heeren RMA. Proteomics Clin Appl. 2019 Jan;13(1):e1800137.
  18. MicroRNAs as a drug resistance mechanism to targeted therapies in EGFR-mutated NSCLC: Current implications and future directions. Leonetti A, Assaraf YG, Veltsista PD, El Hassouni B, Tiseo M, Giovannetti E.  Drug Resist Updat. 2019 Jan;42:1-11.
  19. Ultraviolet Photodissociation of ESI- and MALDI-Generated Protein Ions on a Q-Exactive Mass Spectrometer. Dilillo M, de Graaf EL, Yadav A, Belov ME, McDonnell LA.  J Proteome Res. 2019 Jan 4;18(1):557-564.
  20. Development of a yeast-based system to identify new hBRAFV600E functional interactors. Lubrano S, Comelli L, Piccirilli C, Marranci A, Dapporto F, Tantillo E, Gemignani F, Gutkind JS, Salvetti A, Chiorino G, Cozza G, Chiariello M, Galli A, Poliseno L, Cervelli T. Oncogene. 2019 Feb;38(8):1355-1366.